3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
6
Gynecologic
2
Thoracic
1
Genitourinary
1
Breast
1
Conditions
Carcinoma, Non-Small-Cell Lung
491
Lung Neoplasms
208
Adenocarcinoma of Lung
49
Small Cell Lung Carcinoma
34
Neoplasms
31
Adenocarcinoma, Bronchiolo-Alveolar
25
Neoplasm Metastasis
20
Breast Neoplasms
20
Ovarian Neoplasms
19
Colorectal Neoplasms
16
Carcinoma
14
Squamous Cell Carcinoma of Head and Neck
13
Parkinson Disease 4, Autosomal Dominant Lewy Body
13
Melanoma
13
Carcinoma, Ovarian Epithelial
12
Stomach Neoplasms
11
Carcinoma, Renal Cell
9
Head and Neck Neoplasms
8
Respiratory Tract Neoplasms
7
Prostatic Neoplasms
7
Pancreatic Neoplasms
7
Endometrial Neoplasms
7
Thoracic Neoplasms
6
Pleural Effusion, Malignant
6
Lung Diseases
6
Esophageal Neoplasms
6
Colonic Neoplasms
6
Carcinoma, Squamous Cell
6
Adenocarcinoma
6
Non-Squamous Non-Small Cell Lung Cancer
5
Interventions
pembrolizumab
6
Nivolumab
3
Gemcitabine
3
Cisplatin
3
Carboplatin
3
brigimadlin
2
Ramucirumab
2
Fluorouracil
2
Docetaxel
2
Cetuximab
2
tucatinib
1
trifluridine tipiracil drug combination
1
tremelimumab
1
trametinib
1
regorafenib
1
pertuzumab
1
milademetan
1
larotrectinib
1
futibatinib
1
durvalumab
1
cemiplimab
1
adagrasib
1
Trastuzumab
1
TAS-116
1
Ritonavir
1
Pemetrexed
1
Paclitaxel
1
Oxaliplatin
1
Omacor
1
Leucovorin
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Biliary Tract Neoplasms
×
Paclitaxel
×
Thoracic
×
Clear all
NCT04644068
2026-02-19
PETRA
AstraZeneca
Phase 1/2
Active not recruiting
702 enrolled